GENEPEUTIC BIO CO., LTD.

The First GMP-Compliant Cell and Gene Therapy

Manufacturing Facility in Thailand.

Genepeutic Bio was founded in 2020 to deliver the next wave of personalized cell and gene therapy for patients in Asia, initiating with Chimeric antigen receptor (CAR) T-cells.

CDMO SERVICES

Genepeutic Bio is a contract development and manufacturing organization (CDMO) providing services for CAR T-cells production. Under a GMP-compliant facility, which meets the international standard, we ensure the quality of our products and services for patient’s safety.

CAR T-cell
Manufacturing
Facility

The First GMP-Compliant for Cell and Gene Therapy in Thailand

The facility complies with the international standards utilizing the lastest technology of CAR-T to fight cancer but ensure patient’s safety through extensive list of quality release testings.

CELL AND GENE THERAPY

This technology, classified as advanced therapy medicinal products (ATMPs), utilizes the body’s own immune cells, T-cells, that undergoes gene modification to treat the deliberating diseases such as cancers.

THE PRODUCT

Anti-CD19 CAR T-cells (2nd Generation)

Indications: Relapsed/Refractory CD19 Positive B-cell Malignancies

LATEST NEWS

THEIR OWN MEDICINE : Our Story from The Economist

Biotech entrepreneurs are building on Thailand’s robust industry ecosystem to make advanced health care more accessible.

Genepeutic Bio Gets Supports from Thailand Board of Investment

Thai Board of Investments approves business promotions for 4 new Biotech Project including Genepeutic Bio project for developing advanced cell therapy medicines.

Genepeutic Bio and NSTDA Sign an Investment Deal Agreement

This partnership strengthens the local scientific innovation start-up company and supports Thailand into a medical hub for the therapeutic applications in cell and gene immunotherapies for cancers and other